Major drugmakers are bracing to lose their most lucrative patents this decade

Pharma giants Merck and Bristol-Myers Squibb are both getting ready for some of their key drug patents to expire in the next few years. Both companies reported quarterly earning Thursday, providing insights into how the drug manufacturers are preparing for likely hits to their revenues.

Read more...